Maternal body mass index and pregnancy outcomes: a systematic review and metaanalysis
Importantly, these factors dont just influence GLP-1they are also influenced by GLP-1, especially its effects on metabolic function and appetite regulation
Emerging data have established that GLP-1 agonist administration has not increased the risk of malignancy outside of the thyroid gland and may in fact reduce the risk of malignancy with potential for preventive applications [203,204]
A simple iron panel with ferritin can reveal a correctable cause that, once addressed, may stop the shedding entirely
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
Muscle mass preservation is an important consideration given the risk of sarcopenic obesity: weight loss with GLP-1 RAs includes a lean mass component (approximately 25%-40% of total weight loss), though the clinical significance in MASLD patients without sarcopenia is uncertain